{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:09:21Z","timestamp":1782904161042,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cca.2019.05.014","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T11:28:01Z","timestamp":1558006081000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Substance P in cardiovascular diseases \u2013 A bioanalytical review"],"prefix":"10.1016","volume":"495","author":[{"given":"Martin","family":"Feickert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern B.","family":"Burckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.05.014_bb0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/138945006778019273","article-title":"Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors","volume":"7","author":"Satake","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cca.2019.05.014_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1357-2725(01)00031-0","article-title":"Substance P","volume":"33","author":"Harrison","year":"2001","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cca.2019.05.014_bb0015","first-page":"585","article-title":"Central mechanisms in pain","volume":"83","author":"Urban","year":"1999","journal-title":"Palliat. Med."},{"key":"10.1016\/j.cca.2019.05.014_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.29245\/2572.942X\/2016\/2.1020","article-title":"Substance P and antagonists of the neurokinin-1 receptor in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system","volume":"1","author":"Martinez","year":"2016","journal-title":"J. Neurol. Neuromedicine."},{"key":"10.1016\/j.cca.2019.05.014_bb0025","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.4049\/jimmunol.1002535","article-title":"The tachykinins Substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1, IL-23, and TNF-like 1A expression by monocytes","volume":"186","author":"Cunin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cca.2019.05.014_bb0030","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","article-title":"Neuropeptide Substance P and the immune response","volume":"73","author":"Mashagi","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cca.2019.05.014_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.it.2009.03.006","article-title":"Neurokinin 1 receptor isoforms and the control of innate immunity","volume":"30","author":"Tuluc","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cca.2019.05.014_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.npep.2015.12.005","article-title":"Role of substance P in the cardiovascular system","volume":"58","author":"Mistrova","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.cca.2019.05.014_bb0045","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/0006-2952(90)90257-L","article-title":"The binding of endogenous and exogenous Substance P in human plasma","volume":"39","author":"Corbally","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cca.2019.05.014_bb0050","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ajcn\/62.3.554","article-title":"Immunoreactive peptide (CGRP) substance P and calcitonin-gene-related in rat milk and in human milk and infant","volume":"62","author":"Ducroc","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.cca.2019.05.014_bb0055","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1749-6632.1993.tb18373.x","article-title":"Immunoreactive Substance P in human saliva","author":"Parris","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cca.2019.05.014_bb0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.21053\/ceo.2017.00129","article-title":"Substance P and calcitonin gene-related peptide in the glands of external auditory canal skin","volume":"10","author":"Yoon","year":"2017","journal-title":"Clin. Exp. Otorhinolaryngol."},{"key":"10.1016\/j.cca.2019.05.014_bb0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.biopsych.2012.02.023","article-title":"Cerebrospinal fluid substance P-like immunoreactivity correlates with aggression in personality disordered subjects","volume":"72","author":"Coccaro","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cca.2019.05.014_bb0070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2016.02.003","article-title":"Evidence for involvement of NK3receptors in the anxiogenic-like effect of SP6-11(C-terminal), a metabolite of substance P, in rats evaluated in the elevated plus-maze","volume":"303","author":"Duarte","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.cca.2019.05.014_bb0075","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1440-1819.2009.01936.x","article-title":"Plasma and cerebrospinal fluid substance P in post-stroke patients with depression","volume":"63","author":"Li","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.cca.2019.05.014_bb0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1399-3038.1994.tb00247.x","article-title":"High levels of IgA in HIV 1 perinatally infected children. Antigen specificity and possible role of increased substance P plasma levels","volume":"5","author":"Rossi","year":"1994","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.cca.2019.05.014_bb0085","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2174\/138945006778019291","article-title":"Tachykinins and the cardiovascular system","volume":"7","author":"Walsh","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cca.2019.05.014_bb0090","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1254\/jjp.84.367","article-title":"Actions of tachykinins within the heart and their relevance to cardiovascular disease","volume":"84","author":"Hoover","year":"2000","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.cca.2019.05.014_bb0095","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411001979","article-title":"Diabetic neuropathy and heart failure: role of neuropeptides","volume":"13","author":"Ejaz","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.cca.2019.05.014_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2014.08.004","article-title":"Role of neuropeptides in cardiomyopathies","volume":"61","author":"Dvorakova","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.cca.2019.05.014_bb0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2013.11.010","article-title":"Substance P in heart failure: the good and the bad","volume":"170","author":"Dehlin","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cca.2019.05.014_bb0110","first-page":"1","article-title":"Understanding the complex roles of Substance P in the diseased heart","author":"Levick","year":"2018","journal-title":"Hear. Lung Circ."},{"key":"10.1016\/j.cca.2019.05.014_bb0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1152\/ajpheart.00200.2015","article-title":"Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT","volume":"309","author":"Jubair","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cca.2019.05.014_bb0120","first-page":"1","article-title":"Substance P attenuates hypoxia\/reoxygenation-induced apoptosis via the Akt signalling pathway and the NK1-receptor in H9C2Cells","author":"Xu","year":"2017","journal-title":"Hear. Lung Circ."},{"key":"10.1016\/j.cca.2019.05.014_bb0125","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1161\/01.CIR.99.23.3009","article-title":"Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy","volume":"99","author":"Heymes","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.05.014_bb0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4939-1568-2_8","volume":"1220","author":"Janicki","year":"2015","journal-title":"Mast. Cells"},{"key":"10.1016\/j.cca.2019.05.014_bb0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.109.142042","article-title":"Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart","volume":"55","author":"Levick","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2019.05.014_bb0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/cvr\/cvr244","article-title":"Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells","volume":"92","author":"Mel\u00e9ndez","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cca.2019.05.014_bb0145","doi-asserted-by":"crossref","first-page":"H518","DOI":"10.1152\/ajpheart.00218.2000","article-title":"Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity","volume":"283","author":"Brower","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cca.2019.05.014_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.110.172262","article-title":"Interaction between sensory C-fibers and cardiac mast cells in ischemia\/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction","volume":"335","author":"Morrey","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.cca.2019.05.014_bb0155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/HYPERTENSIONAHA.109.142042","article-title":"Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart","volume":"55","author":"Levick","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2019.05.014_bb0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/039463201302600206","article-title":"Vascular endothelial growth factor (VEGF), mast cells and inflammation","volume":"26","author":"Shaik-Dasthagirisaheb","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.cca.2019.05.014_bb0165","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1016\/j.ijcard.2013.07.190","article-title":"Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension","volume":"168","author":"Dehlin","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cca.2019.05.014_bb0170","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/01.RES.74.5.1009","article-title":"Blockade of cardiac inflammation in Mg2 \u2019 deficiency by Substance P receptor inhibition","volume":"74","author":"Weglicki","year":"1994","journal-title":"Circ. Res."},{"key":"10.1016\/j.cca.2019.05.014_bb0175","first-page":"76","article-title":"Substance P is required for the pathogenesis of EMCV infection in mice","volume":"2","author":"Robinson","year":"2009","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.cca.2019.05.014_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/645153","article-title":"Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis","volume":"2015","author":"Robinson","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cca.2019.05.014_bb0185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00380-009-1189-3","article-title":"Role of substance P in viral myocarditis in mice","volume":"25","author":"Wang","year":"2010","journal-title":"Heart Vessel."},{"key":"10.1016\/j.cca.2019.05.014_bb0190","doi-asserted-by":"crossref","first-page":"46854","DOI":"10.1074\/jbc.M306949200","article-title":"Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus","volume":"278","author":"Zimmer","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2019.05.014_bb0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2796.1991.tb00452.x","article-title":"Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors","volume":"230","author":"Valdemarsson","year":"1991","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2019.05.014_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/147323001204000114","article-title":"Serum levels of calcitonin gene-related peptide and Substance P are decreased in patients with diabetes mellitus and coronary artery disease","volume":"40","author":"Wang","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.cca.2019.05.014_bb0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5012\/bkcs.2014.35.1.158","article-title":"Substance P and neuropeptide y as potential biomarkers for diagnosis of acute myocardial infarction in korean patients","volume":"35","author":"Han","year":"2014","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.cca.2019.05.014_bb0210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"JACC Hear. Fail."},{"key":"10.1016\/j.cca.2019.05.014_bb0215","first-page":"1","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","author":"Nougu\u00e9","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.cca.2019.05.014_bb0220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.npep.2016.06.002","article-title":"Characterization of Substance P processing in mouse spinal cord S9 fractions using high-resolution quadrupole-orbitrap mass spectrometry","volume":"59","author":"Saidi","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.cca.2019.05.014_bb0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0196-9781(94)90212-7","article-title":"Metabolism of substance P and neurokinin a by human vascular endothelium and smooth muscle","volume":"15","author":"Wang","year":"1994","journal-title":"Peptides"},{"key":"10.1016\/j.cca.2019.05.014_bb0230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1471-4159.1985.tb08769.x","article-title":"Substance P in human plasma is degraded by dipeptidyl peptidase IV, not by cholinesterase","volume":"44","author":"Nausch","year":"1985","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2019.05.014_bb0235","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thx.51.2.199","article-title":"Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P","volume":"51","author":"Tomaki","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.cca.2019.05.014_bb0240","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/med.21323","article-title":"Neuropeptides:metabolism to bioactive fragments and the pharmacology of their receptors","volume":"35","author":"Hallberg","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.cca.2019.05.014_bb0245","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchromb.2013.12.025","article-title":"Evaluation of multiple reaction monitoring cubed for the analysis of tachykinin related peptides in rat spinal cord using a hybrid triple quadrupole-linear ion trap mass spectrometer","volume":"947\u2013948","author":"Pailleux","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.cca.2019.05.014_bb0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2460\/ajvr.75.2.109","article-title":"Effects of sample handling methods on substance P concentrations and immunoreactivity in bovine blood samples","volume":"75","author":"Mosher","year":"2014","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.cca.2019.05.014_bb0255","doi-asserted-by":"crossref","first-page":"10157","DOI":"10.1021\/ac502412x","article-title":"Highly sensitive immunoassay for the diagnosis of acute myocardial infarction using silica spheres encapsulating a quantum dot layer","volume":"86","author":"Han","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2019.05.014_bb0260","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1128\/CVI.00174-06","article-title":"Measurement of plasma-derived Substance P: biological, methodological, and statistical considerations","volume":"13","author":"Campbell","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.cca.2019.05.014_bb0265","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/80826","article-title":"Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis","volume":"1","author":"Zhang","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cca.2019.05.014_bb0270","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/bip.22734","article-title":"Membrane-induced structure of novel human tachykinin hemokinin-1 (hHK1)","volume":"103","author":"Ganjiwale","year":"2015","journal-title":"Biopolymers"},{"key":"10.1016\/j.cca.2019.05.014_bb0275","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.bcp.2010.12.007","article-title":"The N-terminal domain of human hemokinin-1 influences functional selectivity property for tachykinin receptor neurokinin-1","volume":"81","author":"Mou","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cca.2019.05.014_bb0280","series-title":"Neuropeptides Substance P-Mediated Cardiac Mast Cell Activation: An In Vitro Study","author":"Levick","year":"2019"},{"key":"10.1016\/j.cca.2019.05.014_bb0285","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejphar.2008.05.049","article-title":"Cardiovascular responses to intravenous administration of human hemokinin-1 and its truncated form hemokinin-1(4-11) in anesthetized rats","volume":"590","author":"Kong","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cca.2019.05.014_bb0290","series-title":"Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells","author":"Tsilioni","year":"2016"},{"key":"10.1016\/j.cca.2019.05.014_bb0295","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mas.20120","article-title":"Mass spectrometry for the quantification of bioactive peptides in biological fluids","volume":"26","author":"Tamvakopoulos","year":"2007","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.cca.2019.05.014_bb0300","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/bmc.1206","article-title":"Identification, characterization and quantification of specific neuropeptides in rat spinal cord by liquid chromatography electrospray quadrupole ion trap mass spectrometry","volume":"23","author":"Beaudry","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cca.2019.05.014_bb0305","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/bmc.703","article-title":"Determination of substance P in rat spinal cord by high-performance liquid chromatography electrospray quadrupole ion trap mass spectrometry","volume":"20","author":"Beaudry","year":"2006","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cca.2019.05.014_bb0310","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1016\/j.chroma.2011.09.072","article-title":"Generic approach for the sensitive absolute quantification of large undigested peptides in plasma using a particular liquid chromatography-mass spectrometry setup","volume":"1218","author":"Sobhi","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.cca.2019.05.014_bb0315","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1601-0825.2010.01717.x","article-title":"Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients","volume":"17","author":"Jang","year":"2011","journal-title":"Oral Dis."},{"key":"10.1016\/j.cca.2019.05.014_bb0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jcpt.12011","article-title":"Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma","volume":"38","author":"Sato","year":"2013","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119318650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119318650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:51:38Z","timestamp":1757861498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119318650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":64,"alternative-id":["S0009898119318650"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.05.014","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substance P in cardiovascular diseases \u2013 A bioanalytical review","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}